A US biopharmaceutical client had to withdraw their ODD application during the COMP’s review procedure, due to the lack of substantial clinical data, as anticipated in VCLS’ feasibility assessment.
Two years on, the client asked VCLS to provide expertise to identify the gaps in the studies and recommend a new approach.
Resources
blog
Embarking on the journey to expand into the United States market is a pivotal moment for any European biotech company.…
blog
Phages, also known as Bacteriophages, are viruses that infect specific bacteria and provoke their death via lytic activity. They are…
blog
2024 is here and will be a crucial year for your clinical trials in the European Union (EU) and European…
blog
In our previous posts, we explored software tools used in digital health and set the foundations around potential applications of…
